Alerts

Since the Trump Administration’s tariff actions began in February 2025, the US hospitality industry has weathered the resulting uncertainty and shown resilience. The industry’s fundamentals remain broadly stable: deals are getting signed, and development continues — albeit with tighter underwriting and recalibrated budgets.

The US Food and Drug Administration (FDA) issued an inspectional observation (Form FDA 483) to a Texas med spa, Pure Indulgence Aesthetics, citing Drug Supply Chain Security Act (DSCSA) violations for dispensers.

Bankruptcy law provides special treatment for landlord claims arising from termination of a lease, using a calculation set forth in Section 502(b)(6) of the Bankruptcy Code. The starting point for the calculation is to identify how and when the termination occurred.

Headlines that Matter for Companies and Executives in Regulated Industries

The enforcement landscape entering 2026 points to sustained False Claims Act activity across traditional health care fraud, AI-enabled misconduct, civil rights–based claims, customs and tariff fraud, and expanding theories of investor liability.

The 2026 District of Columbia elections may be the most consequential elections since the advent of home rule in 1975. Against a backdrop of greater federal intervention into the city’s affairs, depleting federal resources, and local budget pressures, many of the city’s most important local offices will have new leadership after the elections in November.

Last month, the US Food and Drug Administration (FDA) issued a draft guidance explaining how it intends to implement the mandatory recall authority established under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

The telehealth industry is entering a new phase of scrutiny marked by intensified enforcement actions across civil and criminal fronts that reflect a coordinated, whole-of-government approach.

A receivership is a court-supervised tool to stabilize operations of a distressed borrower, ring-fence pledged revenues, and drive recoveries for municipal bondholders when bankruptcy is not available or not desirable.

Last month, a federal court in Maine halted the US Department of Health and Human Services (HHS) Health Resources and Services Administration’s (HRSA) 340B Rebate Model Pilot Program in its tracks — a mere four days before it was to go into effect.

As we approach the end of the first year of the second Trump Administration, many in the health care sector continue to closely watch federal enforcement trends to identify government priorities going forward.

Over the past year, both the executive branch and the courts sought to pare back certain stringent aspects of National Environmental Policy Act (NEPA) reviews. However, a decision issued in December 2025 illustrates that agencies cannot defer conducting NEPA-required reviews until after project approval.

On December 22, 2025, the US Department of Justice (DOJ) sued Stanley Black & Decker in the US District Court for the District of Maryland, alleging violations of the Consumer Product Safety Act (CPSA).

On December 16, 2025, the US Securities and Exchange Commission’s (SEC) Division of Examinations released a risk alert, “Additional Observations Regarding Advisers’ Compliance with the Advisers Act Marketing Rule.”

A federal judge in the Central District of California recently denied a surf apparel brand’s request to halt sales of Lady Gaga’s Mayhem album merchandise.

For the past several years, the use of contract sales forces by pharmaceutical and device manufacturers and other suppliers has been under a heightened enforcement spotlight.

The California Department of Public Health (CDPH) denied two petitions to amend the hospital licensing regulations in Title 22 of the California Code of Regulations to allow advanced practice providers to be members of organized medical staffs in general acute care hospitals.

For the first time in 26 years, the US Food and Drug Administration (FDA) has proposed adding a new active ingredient to the list of permissible sunscreen actives in the United States.

The 2025 holiday retail shopping season is nearly a wrap. Consumers will be on the hunt for year-end discounts, and gift card purchases likely will surge over the coming days.

In this episode of Five Questions, Five Answers, Birgit Matthiesen and Jessica DiPietro explore the historical context and implications of the Nixon Shock and the Trade Expansion Act, focusing on Section 232 investigations and their impact on US trade policy.

On December 18, President Trump issued an executive order (EO) directing the Attorney General to complete rulemaking to reschedule “marijuana” from Schedule I to Schedule III under the Controlled Substances Act (CSA) and to expand federal research and policy development on medical marijuana and hemp derived cannabinoids.

The Centers for Medicare & Medicaid Services (CMS) Innovation Center has announced the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model, a 10‑year voluntary payment model that introduces outcome‑aligned payments (OAPs) to expand access to technology‑supported care for Medicare beneficiaries with common chronic conditions.

A magistrate judge of the US District Court for the District of Delaware issued a report and recommendation recommending the denial of the defendants’ Rule 12(b)(6) motion to dismiss SambaSafety’s Defend Trade Secrets Act (DTSA) claim arising from alleged misappropriation of driver compliance software and related data systems.

On December 19, New York Governor Kathy Hochul vetoed S8432/A8662, a bill to amend the New York LLC Transparency Act that would have decoupled it from the federal Corporate Transparency Act (CTA) definitions.

The past year has been unusually active on the health care antitrust front. Providers are pressing price-fixing and information-exchange theories against payers and claims intermediaries and a landmark class settlement moving into its implementation phase.